Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ThyroSeq overview on indeterminate thyroid nodules: An institutional experience.

Diagnostic cytopathology - 1 Jul 2024

Sirotnikov Sam, Griffith Christopher C, Lubin Daniel, Zhang Chao, Saba Nabil F, Li Dehong, Kornfield Amanda, Chen Amy, Shi Qiuying

Abstract excerpt

BACKGROUND: Molecular triage of indeterminate thyroid aspirates offers the opportunity to stratify the risk of malignancy (ROM) more accurately. Here we examine our experience with ThyroSeq v3 testing. METHODS: We analyzed 276 of 658 (42%) fine needle aspiration samples classified as indeterminate thyroid nodules using ThyroSeq v3 (Sept 2017-Dec 2019). The test provides a ROM and detects specific mutations....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biopsy, Fine-Needle

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Thyroid Neoplasms

Share to Thyroid Nodule

Source

Identifiers

PMID: 38554032
DOI: 10.1002/dc.25311

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ThyroSeq overview on indeterminate thyroid nodules: An institutional experience.PMID 38554032Read ↗

High-risk and intermediate-high-risk results from the ThyroSeq v2 and v3 thyroid genomic classifier are associated with neoplasia: Independent performance assessment at an academic institution.Semantic proximity Read ↗

Risk stratification of ThyroSeq results in indeterminate thyroid lesions: A single-institution experience of clinicopathologic correlation with cytologic findings.Semantic proximity Read ↗

Molecular Profiling of 50 734 Bethesda III-VI Thyroid Nodules by ThyroSeq v3: Implications for Personalized Management.Semantic proximity Read ↗

The utility of ThyroSeq® in the management of indeterminate thyroid nodules by fine-needle aspiration.Semantic proximity Read ↗

Correlation of ThyroSeq Results with Surgical Histopathology in Cytologically Indeterminate Thyroid Nodules.Semantic proximity Read ↗

Inter-institutional variation in predictive value of the ThyroSeq v2 genomic classifier for cytologically indeterminate thyroid nodulesSemantic proximity Read ↗

Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.Semantic proximity Read ↗

The Role of the ThyroSeq v3 Molecular Test in the Surgical Management of Thyroid Nodules in the Canadian Public Health Care Setting.Semantic proximity Read ↗

Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.Semantic proximity Read ↗

Malignancy Risk, Molecular Mutations, and Surgical Outcomes of Thyroid Nodules Classified as Atypia of Undetermined Significance in the Bethesda System: A Comprehensive Analysis.Semantic proximity Read ↗

ThyroSeq®V2.0 Molecular Testing: A Cost-Effective Approach for the Evaluation of Indeterminate Thyroid Nodules.Semantic proximity Read ↗

Molecular Profiling for Bethesda III to VI Nodules: Results of a Multicenter International Retrospective Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.